Basic Information
| LncRNA/CircRNA Name | GAS6-AS2 |
| Synonyms | NA |
| Region | GRCh38_13:113864168-113866833 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay etc |
| Sample | OS tissues,cell lines(HOS, U2OS and 143B) |
| Expression Pattern | up-regulated |
| Function Description | Highly expressed GAS6-AS2 in OS was associated with poor prognosis.GAS6-AS2 deficiency inhibited OS cell proliferation and promoted apoptosis in vitro. |
| Pubmed ID | 32269179 |
| Year | 2020 |
| Title | USF1-mediated upregulation of lncRNA GAS6-AS2 facilitates osteosarcoma progression through miR-934/BCAT1 axis |
External Links
| Links for GAS6-AS2 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |